Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTA Centessa Pharmaceuticals	$17.14 -1.0%	$14.13	$9.60 ▼ $19.09	$2.31B	1.48	1.16 million shs	1.47 million shs
DNLI Denali Therapeutics	$14.35 +0.4%	$14.27	$10.57 ▼ $33.33	$2.08B	1.36	1.58 million shs	2.32 million shs
HRMY Harmony Biosciences	$34.67 -0.8%	$34.16	$26.47 ▼ $41.61	$2.01B	0.84	627,095 shs	652,294 shs
SLDB Solid Biosciences	$6.51 -2.8%	$5.28	$2.41 ▼ $10.37	$519.35M	2.44	1.47 million shs	1.11 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTA Centessa Pharmaceuticals	-0.98%	+3.50%	+25.84%	+37.78%	+59.44%
DNLI Denali Therapeutics	+0.42%	+4.97%	+0.70%	-0.55%	-34.77%
HRMY Harmony Biosciences	-0.77%	-2.28%	+7.54%	+1.70%	+5.60%
SLDB Solid Biosciences	-2.84%	-7.92%	+32.59%	+135.02%	-18.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CNTA Centessa Pharmaceuticals	3.2014 of 5 stars	3.5	3.0	0.0	2.6	3.3	0.6
DNLI Denali Therapeutics	4.1339 of 5 stars	3.6	1.0	4.7	3.2	3.3	0.0
HRMY Harmony Biosciences	4.7171 of 5 stars	4.5	1.0	0.0	3.3	3.3	4.4
SLDB Solid Biosciences	3.0275 of 5 stars	4.6	1.0	0.0	2.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTA Centessa Pharmaceuticals	3.00	Buy	$28.10	63.94% Upside
DNLI Denali Therapeutics	3.12	Buy	$33.85	135.86% Upside
HRMY Harmony Biosciences	3.00	Buy	$51.00	47.10% Upside
SLDB Solid Biosciences	3.17	Buy	$15.10	131.95% Upside

Current Analyst Ratings Breakdown

Latest SLDB, HRMY, DNLI, and CNTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	CNTA Centessa Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/28/2025	DNLI Denali Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/21/2025	CNTA Centessa Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/21/2025	HRMY Harmony Biosciences	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$48.00
7/10/2025	HRMY Harmony Biosciences	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $55.00
7/10/2025	HRMY Harmony Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$33.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	SLDB Solid Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$15.00

(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTA Centessa Pharmaceuticals	$6.85M	334.34	N/A	N/A	$3.05 per share	5.62
DNLI Denali Therapeutics	$330.53M	6.31	N/A	N/A	$8.53 per share	1.68
HRMY Harmony Biosciences	$714.73M	2.79	$2.92 per share	11.86	$13.46 per share	2.58
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	$3.43 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTA Centessa Pharmaceuticals	-$235.76M	-$1.81	N/A	N/A	N/A	N/A	-40.22%	-29.95%	8/12/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	8/7/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	11.18	11.15	0.48	23.44%	26.34%	17.71%	N/A
SLDB Solid Biosciences	-$124.70M	-$2.99	N/A	N/A	N/A	N/A	-68.15%	-55.33%	8/12/2025 (Estimated)

Latest SLDB, HRMY, DNLI, and CNTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CNTA Centessa Pharmaceuticals	-$0.34	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	$5.64 million	N/A
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/12/2025	Q1 2025	CNTA Centessa Pharmaceuticals	-$0.35	-$0.20	+$0.15	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTA Centessa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTA Centessa Pharmaceuticals	0.28	14.37	14.37
DNLI Denali Therapeutics	N/A	9.56	9.56
HRMY Harmony Biosciences	0.20	3.84	3.63
SLDB Solid Biosciences	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTA Centessa Pharmaceuticals	82.01%
DNLI Denali Therapeutics	92.92%
HRMY Harmony Biosciences	86.23%
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
CNTA Centessa Pharmaceuticals	7.09%
DNLI Denali Therapeutics	12.50%
HRMY Harmony Biosciences	23.60%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTA Centessa Pharmaceuticals	200	133.62 million	124.15 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
SLDB Solid Biosciences	100	77.52 million	76.04 million	Optionable

SLDB, HRMY, DNLI, and CNTA Headlines

Recent News About These Companies

Solid Biosciences (SLDB) Projected to Post Earnings on Tuesday

August 6 at 11:54 AM | marketbeat.com

Solid Biosciences (NASDAQ:SLDB) Stock Price Down 3.4% - What's Next?

August 5 at 2:35 PM | marketbeat.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 1, 2025 | globenewswire.com

Solid Bio Green on Fast Track Nod

July 23, 2025 | baystreet.ca

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

July 23, 2025 | globenewswire.com

Solid Biosciences (NASDAQ:SLDB) Trading 13.3% Higher - Should You Buy?

July 19, 2025 | marketbeat.com

What is HC Wainwright's Estimate for SLDB FY2027 Earnings?

July 16, 2025 | marketbeat.com

Solid Biosciences Inc. (NASDAQ:SLDB) Receives Consensus Recommendation of "Buy" from Analysts

July 16, 2025 | marketbeat.com

SLDB - Solid Biosciences Inc Executives - Morningstar

July 15, 2025 | morningstar.comM

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm

July 10, 2025 | prnewswire.com

SLDB Solid Biosciences Inc. - Seeking Alpha

July 10, 2025 | seekingalpha.com

Solid Biosciences receives FDA approval for CPVT gene therapy IND

July 10, 2025 | investing.com

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular ... - Yahoo Finance

July 10, 2025 | finance.yahoo.com

Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT

July 10, 2025 | msn.com

Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes

July 9, 2025 | msn.com

SLDB - Solid Biosciences Inc Price vs Fair Value - Morningstar

July 8, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) - Yahoo Finance

July 2, 2025 | finance.yahoo.com

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

SLDB - Solid Biosciences Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Citigroup Initiates Coverage of Solid Biosciences (SLDB) with Buy Recommendation

June 26, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLDB, HRMY, DNLI, and CNTA Company Descriptions

Centessa Pharmaceuticals NASDAQ:CNTA

$17.14 -0.17 (-0.98%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$17.14 0.00 (0.00%)

As of 04:04 AM Eastern

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Denali Therapeutics NASDAQ:DNLI

$14.35 +0.06 (+0.42%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$14.35 +0.00 (+0.01%)

As of 04:05 AM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$34.67 -0.27 (-0.77%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$34.83 +0.16 (+0.45%)

As of 08/6/2025 05:33 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Solid Biosciences NASDAQ:SLDB

$6.51 -0.19 (-2.84%)

Closing price 08/6/2025 04:00 PM Eastern

Extended Trading

$6.09 -0.42 (-6.45%)

As of 04:00 AM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time